Our mission
Genomic answers, within reach of every patient.
Targeted cancer therapy depends on knowing a tumor's mutations, yet most patients never get that information. Imagenomix exists to change that, using AI to predict genetics from the pathology slides every patient already has.
The gap
A diagnosis is not the same as an answer.
Knowing which mutations drive a tumor is what makes targeted therapy possible. For most patients, that knowledge never arrives, blocked by cost, tissue, or turnaround.
never receive molecular testing.
never receive molecular testing.
of samples are insufficient for sequencing — even patients who are tested can be turned away.
Imagenomix closes the gap
IGX Predict runs on every confirmed cancer case — reading actionable genetics from the standard H&E slide already on the bench.
These are genomically underserved patients. Imagenomix exists to bridge that gap.
Why it matters: when a tumor's drivers are known, patients can be matched to targeted therapies that meaningfully improve outcomes. Testing is the door to that treatment, and today it stays closed for most.
Access to molecular testing, United States and worldwide.
A first in cancer AI
The first to predict cancer mutations from a single image.
Imagenomix pioneered predicting a tumor's genetics from its histology, then proved it, patented it, and brought it to the clinic.
- 2017DiscoveredHistology-based mutation prediction shown at NYU Langone.
- 2018First to publishCoudray et al., Nature Medicine.
- 2018 to 2022ProvenValidated across multiple cancer types.
- 2022PatentedUS Patent 11,367,180.
- 2023CommercializedIGX Predict goes live.
How it works
The answer is already in the tissue.
Every test begins with an H&E stained slide. Imagenomix partitions that whole slide image into thousands of tiles, scores each one for the molecular signatures of driver mutations, then maps the result back onto the slide.
No DNA extraction. No additional tissue. The genetics, predicted directly from the image.
Why IGX Predict
Fast. Affordable. Accessible.
Predictions in minutes, not the weeks sequencing can take. Treatment decisions cannot wait.
Computational, not wet-lab, bringing molecular insight within reach of every confirmed cancer case.
Runs on the standard H&E slide every patient already has, using the scanners and image systems labs already own.
For research use. Performance varies by product, see each product page for validation detail.
The platform
IGX Predict™One platform. Four products. Four cancer types.
IGX Predict is the platform. Its engines prepare each case, then a tumor-type product predicts the driver mutations from the standard H&E slide.
Four products across four cancer types. Pulmogene is commercial. BLISS, NeuroInsight, and DermPredict are in development.
Access and equity
No patient left untested.
Health outcomes should not depend on where a patient lives or where their sample is sent. Our models are trained across diverse patient populations so they perform accurately across racial and ethnic backgrounds, not only in well-resourced cohorts.
Imagenomix was selected for the AWS Health Equity Initiative to scale IGX Predict toward genomically underserved patients in every country, the foundation for reaching patients who would otherwise have no path to molecular testing at all.
Where we began
Spun out of NYU Langone.
Imagenomix grew out of research at NYU Langone Health showing that a tumor's genetics leave readable traces in its histology. We licensed that technology, assembled a team of AI scientists, pathologists, and oncologists, and set out to bring it to patients.
Work with us
Two ways to bring genetics to every image.
For pathology practices
Molecular insight in minutes
Run IGX Predict on confirmed cancer cases and return driver mutation predictions with spatial heatmaps, without sending tissue out or waiting weeks.
See the platform
For biopharma partners
Screen archives, enrich trials
Prescreen archival slides for molecular drivers to find eligible cases faster and spatially map heterogeneity before more expensive sequencing.
Explore partnershipsHelp us reach the patients no one is testing.
Whether you are a clinician, a sponsor, or a future colleague, there is a place for you in this. Reach the team to run a case, pilot the platform, or partner on a trial.
Imagenomix Corp · New York, NY · Contact